-+ 0.00%
-+ 0.00%
-+ 0.00%

MBX BIOSCIENCES, - PHASE 3 OPTIMIZE TRIAL TO ENROLL ABOUT 160 ADULTS WITH HYPOPARATHYROIDISM

路透·08/27/2026 12:00:02

登录查看新闻详情